Biotech

Xeno Cell Innovations

XENO Cell Innovations is a biotechnology company whose mission it is to simplify diagnostic processes through advancements in biotechnological intelligence. XENO aims to revolutionise early disease detection by completely rethinking diagnostics, making detection of biomarkers easier, faster, cheaper and, consequently, more accessible to the general population. XENO comprises a diverse cohort of engineers and biologists—all driven to bring about unprecedented advancements in diagnostic biotechnology, providing physicians with the means to make better informed decisions and thus improve survival rates.

Supporting the doctor´s laboratory Zuzana Kečkéšová

Doctor Zuzana Kečkéšová pursues the research of new tumor suppressors. One such substance is, for example, LACTB, a protein that kills cancer cells in certain conditions. This project runs under the supervision of Professor Jan Konvalinka at the Institute of Organic Chemistry and Biochemistry in Prague. Dr. Kečkéšová has based her study on research of those human organs that are not susceptible to cancer – such as muscles including cardiac muscle or very rarely susceptible to cancer such as spleen or cartilage. Cancer does not form in these organs and it does not spread to these organs from elsewhere.

DIANA Biotech

DIANA Biotech is an analytical and diagnostic method that is more versatile and accurate than other commercially available methods (for example, ELISA). DIANA is very accurate in determining the number of enzymes and other proteins in solutions such as human blood, urine or even saliva. As a result, physicians should be able to diagnose cancer or various infectious diseases at a stage where they are not detectable by current means. DIANA's technology was developed in the lab of Jan Konvalinka, at Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, by Vaclav Navratil, who won the Werner von Siemense Prize.

Nannuncio

Nanuncio focuses on the research, development, registration and production of nano-fiber materials and bio-materials for use in medicine and cosmetics. The main goal in this area is the production of non-adhesive wound covers for professional use, which, thanks to their unique properties, can be enriched with other ingredients and active substances. Nanuncio, headed by Professor Evžen Amler, has its seat in the Czech Republic.

Finch Therapeutics Group

Finch Therapeutics focuses on the research of broad-spectrum microorganisms for the treatment of common or unspecified intestinal inflammations (IBD). Intestinal diseases are one of the most common and most prevalent diseases in the world, with up to 60% of patients who had antibiotic treatment in the past are prone to antibiotic resistance while treatment with broad spectrum micro-organisms reaches up to 88% success.

Ginkgo Bioworks

Ginkgo Bioworks focuses on the genetic modification of organisms and the research of enzyme development, which are the main catalysts for chemical reactions, determining their nature and speed. After finding the right enzymes and their combinations, Ginkgo genetically modifies yeasts that can produce almost anything from the scent of rose to peach oil. These technologies can be used in the food, pharmaceutical and cosmetic industries.

Project - medical foods

A leading immunology company focused on microbial research (the body's microorganism system) and its impact on our organism. The company focuses primarily on the development and registration of microbial nutraceuticals. The lead investor of the company is one of America's most successful venture capital fund.

Scipher Medicine

Scipher Medicine focuses on developing a method that, based on a simple test, will be able to determine if and how our molecular profiles will respond to the prescribed drugs. The method can predict the efficacy of treatment for patients with a high degree of accuracy. This goal is achieved by linking blood diagnostics with bio-informatics.

Q2 Pharma

The company focuses on drug research against "superbacteria" which are resistant to available antibiotics. One of these bacteria is the gold staphylococcus (MRSA). This bacterium most commonly causes infectious diseases of the skin and nasal cavities. However, there can be large-scale infection with fatal consequences when the bacteria enter the body via open wounds.

Project - computer technology

The New Drug Identification Platform, led by a team of top scientists from Standford University with experience in genomics, synthetic biology, chemistry and computer science. The company uses computational biology to collect data, and then analyze and identify pharmaceuticals derived from natural sources.